Latest TEM news

3 Analysts, 3 Trades to Make Today

InvestorPlace · Tue, 22 Sep 2026 17:00:00 -0400

On any given day, there's a headline, a fear, or a worry screaming for your attention. We regularly cover those headlines here, doing our best to separate the signal from the noise so you can keep moving toward your financial goals.

Tempus AI: High Risk, But With A Great Cause

Seeking Alpha · Tue, 22 Sep 2026 07:05:46 -0400

Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. TEM's acquisition of Personalis fills a critical MRD monitoring gap, unlocking recurring revenue and enhancing AI data assets. Q2 2026 saw 22% revenue growth, improved margins, and raised full-year guidance, despite continued operating losses.

Tempus AI: Data And Applications Will Unlock More Upside

Seeking Alpha · Mon, 21 Sep 2026 23:37:10 -0400

Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.

Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion

MarketBeat · Mon, 21 Sep 2026 20:02:20 -0400

Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model

Business Wire · Mon, 21 Sep 2026 09:14:00 -0400

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co.

This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga · Mon, 21 Sep 2026 08:38:06 -0400

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Tempus AI stock is soaring: does it have more upside to go?

Invezz · Fri, 18 Sep 2026 09:30:00 -0400

Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.

Market information is provided for research and visualization and is not investment advice.